Current advances in cancer immunohistochemistry: a new perspective for the Ki-67 biomarker.

IF 1.2 Q4 ONCOLOGY
ecancermedicalscience Pub Date : 2025-03-05 eCollection Date: 2025-01-01 DOI:10.3332/ecancer.2025.1863
Talita Alves do Nascimento Santos, Anna Karoline Fausto da Silva, Karin Soares Gonçalves Cunha, Camila Braz Pereira da Costa, Aldo Rodrigues da Silva, Helena Carla Castro, Nathália Silva Carlos Oliveira
{"title":"Current advances in cancer immunohistochemistry: a new perspective for the Ki-67 biomarker.","authors":"Talita Alves do Nascimento Santos, Anna Karoline Fausto da Silva, Karin Soares Gonçalves Cunha, Camila Braz Pereira da Costa, Aldo Rodrigues da Silva, Helena Carla Castro, Nathália Silva Carlos Oliveira","doi":"10.3332/ecancer.2025.1863","DOIUrl":null,"url":null,"abstract":"<p><p>Ki-67 is a cell proliferation biomarker used to evaluate the proliferative activity of neoplasia cells. However, considering its functions on the cell cycle, the standard method seems to be an underused way of evaluating expression, since so far, its analytical validity of Ki-67 remains questionable for its use in personalised therapy. Improvements in the assessment of Ki-67 expression continue to be explored, and recently, a new approach that considers the heterogeneity or variability in staining intensity has emerged as a more improved way than the traditional method. In this review, we bring together what is available in the literature on the biological properties of the protein and highlight how this potential association is promising in the field of personalised medicine.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1863"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146573/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2025.1863","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ki-67 is a cell proliferation biomarker used to evaluate the proliferative activity of neoplasia cells. However, considering its functions on the cell cycle, the standard method seems to be an underused way of evaluating expression, since so far, its analytical validity of Ki-67 remains questionable for its use in personalised therapy. Improvements in the assessment of Ki-67 expression continue to be explored, and recently, a new approach that considers the heterogeneity or variability in staining intensity has emerged as a more improved way than the traditional method. In this review, we bring together what is available in the literature on the biological properties of the protein and highlight how this potential association is promising in the field of personalised medicine.

肿瘤免疫组化进展:Ki-67生物标志物的新视角
Ki-67是一种用于评价肿瘤细胞增殖活性的细胞增殖生物标志物。然而,考虑到其在细胞周期中的功能,标准方法似乎是一种未被充分利用的评估表达的方法,因为到目前为止,Ki-67在个性化治疗中的分析有效性仍然值得怀疑。Ki-67表达评估的改进仍在继续探索,最近,一种考虑染色强度异质性或可变性的新方法已经出现,是一种比传统方法更改进的方法。在这篇综述中,我们汇集了关于蛋白质生物学特性的现有文献,并强调了这种潜在的关联在个性化医学领域的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
5.60%
发文量
138
审稿时长
27 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信